Dynavax Demonstrates Ability Of Immunostimulatory DNA Sequences To Inhibit Symptoms Of Allergic Asthma In An...( BERKELEY CA (December 15 1998): Inj...)

Dynavax Demonstrates Ability Of Immunostimulatory DNA Sequences To Inhibit Symptoms Of Allergic Asthma In Animal Model

BERKELEY, CA (December 15, 1998): Injections of proprietary immunostimulatory DNA sequences (ISS-DNA), under development by Dynavax Technologies Corporation, can alter the nature of the immune response in allergic asthma, while also inhibiting the symptoms of that disease, the company announced. Dynavax scientists and their collaborators published research in the December 15 issue of the Journal of Immunology showing that a single systemic or mucosal (intranasal or intratracheal) administration of ISS-DNA in an animal model of allergic asthma inhibited disease symptoms as effectively as systemic corticosteroids administered daily for seven days. Moreover, unlike the corticosteroids, ISS-DNA injections were able to redirect the immune response away from the strong Th2 response associated with allergic inflammation toward a non-allergic Th1 response.

"This study demonstrates in vivo, for the first time, that ISS-DNA can be used as a drug to both inhibit and modify allergic disease," said Dino Dina, M.D., president and chief executive officer of Dynavax. "In fact, our lead ISS-DNA molecule has proven active in every animal species that Dynavax scientists and their collaborators have tested to date, including primates. Based on their research, we believe that ISS-DNA therapy may provide a totally novel, highly effective therapy for chronic allergic pulmonary inflammation."

The Journal of Immunology study was authored by Dynavax founder, Eyal Raz, M.D. and David Broide, M.B. Ch.B. of the Department of Medicine, University of California, San Diego; and their collaborators Helen Tighe, Ph.D., Minh-Duc Nguyen, and Siamak Malek at Dynavax; Tim Gifford and John Van Uden at the University of California, San Diego; and Jurgen Schwarze, M.D. and Erwin W. Gelfand, M.D. at the Department of Pediatrics, National Jewish Medical and Research Center in Denver, CO.

In the study, the researchers used a mouse model of allergen-induced airway hyperresponsiveness to investi
'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
15-Dec-1998

Page: 1 2 3
Related medicine news :

1. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
2. New Report Demonstrates That Following Guidelines Improves Clinical Practices, Reduces Liability Costs
3. Study Demonstrates The Benefits Of Mammography In Women Under 50
4. Study Demonstrates Safety & Effectiveness Of Asthma Drug
5. Inhibitors prevent aggresome formation associated with some forms of ALS
6. Inhibiting Growth Of New Blood Vessels Reduces Heart Disease Plaque In Mice
7. Acetylcholinesterase Inhibitors May Be Another Piece In Alzheimers Jigsaw
8. New Protease Inhibitor Could Thwart AIDS Resistance To Current Drugs
9. Hunter College Biologist Marie Filbin Identifies Mechanism That Blocks All Inhibitors Of Nerve Regeneration; Breakthrough Reported In Neuron Magazine
10. Antabuse May Inhibit Fatal Reaction To Anesthetic
11. HIV Patients Treated With Protease Inhibitors Are More Likely To Engage In Risky Sex, Emory Researchers Report

Post Your Comments: